Multiparametric and dynamic criteria to consider the best choice of treatment for TE patients with NDMM. ASCT, autologous stem cell transplantaon; CAR T, chimeric antigen receptor; EMD, extramedullary disease; HD, high dose; HR, high risk; MRD, minimal residual disease; PCL, plasma cell leukemia; SR, standard risk.